tradingkey.logo
tradingkey.logo
Search

Beta Bionics Inc

BBNX
Add to Watchlist
16.760USD
+0.060+0.36%
Close 07/02, 13:00ETQuotes delayed by 15 min
746.85MMarket Cap
LossP/E TTM

TradingKey Stock Score of Beta Bionics Inc

Currency: USD Updated: 2026-07-02

Key Insights

Beta Bionics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.58.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beta Bionics Inc's Score

Industry at a Glance

Industry Ranking
40 / 204
Overall Ranking
114 / 4565
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Beta Bionics Inc Highlights

StrengthsRisks
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 735.77% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 100.25M.
Fairly Valued
The company’s latest PE is -12.27, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.25M shares, decreasing 4.25% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 2.18M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
19.583
Target Price
+15.20%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Beta Bionics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Beta Bionics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Beta Bionics Inc’s performance and outlook.

How do we generate the financial health score of Beta Bionics Inc?

To generate the financial health score of Beta Bionics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Beta Bionics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Beta Bionics Inc.

How do we generate the company valuation score of Beta Bionics Inc?

To generate the company valuation score of Beta Bionics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Beta Bionics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Beta Bionics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Beta Bionics Inc.

How do we generate the earnings forecast score of Beta Bionics Inc?

To calculate the earnings forecast score of Beta Bionics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Beta Bionics Inc’s future.

How do we generate the price momentum score of Beta Bionics Inc?

When generating the price momentum score for Beta Bionics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Beta Bionics Inc’s prices. A higher score indicates a more stable short-term price trend for Beta Bionics Inc.

How do we generate the institutional confidence score of Beta Bionics Inc?

To generate the institutional confidence score of Beta Bionics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Beta Bionics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Beta Bionics Inc.

How do we generate the risk management score of Beta Bionics Inc?

To assess the risk management score of Beta Bionics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Beta Bionics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Beta Bionics Inc.